Atlas Trials

A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

Clinical trial NCT04224688 · TERMINATED

Trial details

NCT number
NCT04224688
Sponsor
UCB Biopharma SRL
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Primary Immune Thrombocytopenia
Start date
2020-06-03
Primary completion
2022-04-25
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.